Our Story

Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights, and assets from The DuPont Merck Pharmaceutical Company.  Endo International plc has transformed into a global specialty healthcare company focused on improving patients' lives while creating value. Endo develops manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices through its operating companies. Endo has global headquarters in Dublin, Ireland and US headquarters in Malvern, PA. 

History Timeline

2014

On February 3, 2014, Endo successfully completed its acquisition of specialty generics company Boca Pharmacal. Boca focuses on niche areas, commercializing and developing products in categories that include: controlled substances, semisolids and solutions. Boca Pharmacal’s commercial footprint and R&D pipeline is expected to be a strong complement to Qualitest. 

On February 3, 2014, Endo completed its divestiture of HealthTronics to Altaris Capital Partners, LLC.


2014

2013

In January 2013, Endo Corporate Headquarters moves from Chadds Ford to a newly constructed building at the Atwater Campus in Malvern, PA.

On February 25, Rajiv De Silva is named President, Chief Executive Officer and a Director of Endo.

In June 2013, Endo announces strategic change to focus on providing quality healthcare products through distinct operating companies, and announces restructuring to improve operating margins.

2013

2012

In February 2012, Endo announces the aggregation of its operating companies as part of an enterprise-wide branding initiative; announces corporate name change to Endo Health Solutions.

December 2012, Endo’s board announces the retirement of President and CEO Dave Holveck.

2012

2011

On January 28, 2011, Endo enters into a collaboration agreement with Orion Corporation for the discovery, development and commercialization of assets in Oncology.

On March 3, 2011, Endo Launches FORTESTA® (Testosterone) Gel.

On June 20, 2011, American Medical Systems Inc (AMS) becomes a wholly owned subsidiary of Endo Pharmaceuticals.

2011

2010

On July 15,2010, HealthTronics, Inc. becomes an affiliate of Endo Pharmaceuticals.

On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 1, 2010, Qualitest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.

On December 29, 2010, the U.S. Food and Drug Administration approved FORTESTA® Gel.

2010

2009

On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of Indevus Pharmaceuticals, Inc. Indevus brought us multiple marketed products that enhance revenue growth, a specialized infrastructure focused in urology, endocrinology and oncology, and a strong drug-development pipeline.

Endo relaunches VALSTAR®.

2009

2008

Endo entered into a licensing agreement with Novartis to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren® Gel (diclofenac sodium topical gel) 1%. Voltaren Gel received regulatory approval in October 2007 from the U.S. Food and Drug Administration.

David Holveck is named President, Chief Executive Officer and a Director of Endo. A new executive team is created to take Endo to the next level.

2008

2007

Roger Kimmel appointed chairman of the Board; Carol Ammon retired.

Endo entered into a license and development agreement with Alexza Pharmaceuticals, Inc. for the exclusive clinical development and commercialization rights in North America for Alexza's AZ-003/ EN3294. Currently in Phase I, clinical development, AZ-003 is a hand-held drug device system that uses Alexza's proprietary Staccato® system inhalation technology to deliver fentanyl.

2007

Net sales : 1,085.6 millions

Employees : 1,208

2007

2006

Endo received FDA approval for OPANA® and OPANA® ER, which represented the first internally developed NDAs to be granted FDA approval.

Endo Pharmaceuticals acquires RxKinetix Inc. through an acquisition. The acquisition broadens Endo pipeline with supportive care oncology products, including EN3285, a topical oral-rinse for the prevention of oral mucositis.

2006

Net sales : 909.7 millions

Employees : 1,024

2006

2005

Endo Pharmaceuticals acquired exclusive licenses from DURECT Corporation to develop and commercialize a seven-day transdermal sufentanil patch (EN3270).

2005

Net sales : 820.2 millions

Employees : 710

2005

2004

Endo entered into an agreement with Vernalis for the exclusive rights to market FROVA® in North America. Launched in the U.S. in June 2002.

2004

Net sales : 615.1 millions

Employees : 594

2004

2003

Endo further expands its internal sales force by converting the contract pharma sales force, district managers and regional directors to full-time Endo employees.

2003

Net sales : 595.6 millions

Employees : 492

2003

2002

Endo established its first internal sales force when it converted the contract specialty sales force and district managers into full-time employees to concentrate sales efforts.

Endo reached $1 billion dollars in cumulative sales.

2002

Net sales : 399 millions

Employees : 277

2002

2001

Endo receives FDA approval for PERCOCET® strengths (7.5/325 and 10/325 oxycodone/acetaminophen).

2001

Net sales : 252 millions

Employees : 167

2001

2000

Endo Pharmaceuticals acquired Algos Pharmaceutical Corporation through a merger. As a result of this merger, Endo Pharmaceuticals became a publicly traded company, under the NASDAQ symbol ENDP.

2000

Net sales : 197.4 millions

Employees : 135

2000

1999

Endo launched three strengths of its leading brand-name drug PERCOCET®. After receiving FDA approval, Endo launched LIDODERM® as its first proprietary, patented product.

1999

Net sales : 135.5 millions

Employees : 92

1999

1998

Endo licensed LIDODERM® from Hind Healthcare.

1998

Net sales : 108.4 millions

Employees : 70

1998

1997

Three executives of DuPont Merck acquired certain products from DuPont Merck in a management buyout for $277 million with financing from Kelso & Company, a private equity investment firm purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including PERCOCET® and PERCODAN®.

1997

Net sales : 39.4 millions

Employees : 62

1997

Intravenous Products of America, Inc. changed its name to Endo Products

The history of Endo can be traced back to 1920 to a family-run pharmaceutical company originally called Intravenous Products of America, Inc. In 1935 Intravenous Products of America, Inc. changed its name to Endo Products.

In 1950, PERCODAN® was launched.

In 1970, E.I. du Pont de Nemours and Company (DuPont) acquired Endo. In 1971, PERCOCET® was launched.

In 1994, DuPont Merck reestablished Endo as a separate entity within the company. This entity was named Endo Laboratories L.L.C. and served as DuPont Merck's generic division.

Intravenous Products of America, Inc. changed its name to Endo Products